GlobeNewsWire
10 Nov 2025, 21:05 UTC · 44w ago
Verdict
Headline takes no side. We score MLYS +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Mineralys Therapeutics plans to submit a New Drug Application (NDA) for lorundrostat in late 2025 or Q1 2026.
More positive than 98% of claims this week
The company has $593.6 million in cash, equivalents, and investments, which it expects will fund operations into 2028.
So whatStrong liquidity reduces the immediate risk of dilutive financing and provides a significant runway to reach the NDA decision.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Topline results for the Explore-OSA trial are anticipated in Q1 2026.
More positive than 77% of claims this week
Net loss for Q3 2025 decreased to $36.9 million from $56.3 million in the prior year period.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company is progressing toward an NDA submission for lorundrostat, reporting a reduced net loss and a strong cash position to fund operations into 2028.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1h ago
−35.5%
Price is moving against the score
$28.71 vs $44.50 close before publication (Nov 10) · not market-adjusted
MLYS chart →
